Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor
Journal of Medicinal Chemistry · 21.11.2026
DOI: 10.1021/acs.jmedchem.6c02053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 21.11.2026. Verfasst von Hugh N. Nuthall und 21 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Postmortem brain examinations in Alzheimer’s disease (AD) reveal β-amyloid plaques, neurofibrillary tangles resulting from tau protein aggregation, and neuronal and synaptic loss, which collectively impair brain function. O-linked N-acetylglucosami-nidase (OGA) is an enzyme that removes O-linked β-N-acetylglucosamine (O-GlcNAc) from proteins including tau. In animal tauopathy models, OGA inhibition was shown to increase O-GlcNAc−tau levels, leading to reduced tau hyperphosphorylation and aggregation. These results inspired efforts to develop OGA inhibitors for the treatment of AD and tauopathies. Here we report the discovery and clinical development of ceperognastat (LY3372689), a low-dose, CNS-penetrant OGA inhibitor that has been evaluated in a completed phase II study in patients with early symptomatic AD.
Förderung
- Eli Lilly and Company
Zitieren
APA
Nuthall, H. N., Kielbasa, W., Woerly, E. M., Hendle, J., Goldsmith, P., Dubois, S. L., Zhang, F. F., Donnelly, K. B., Fleisher, A. S., Lowe, S. L., Shcherbinin, S., Winneroski, L. L., Lopez, J. E., Dreyfus, N. J., Evans, D. A., Lindsay-Scott, P. J., Rathmell, R. E., Gilmore, J., Collins, E. C., …, & Mergott, D. J. (2026). Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c02053
Vancouver
Nuthall HN, Kielbasa W, Woerly EM, Hendle J, Goldsmith P, Dubois SL, et al. Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c02053
BibTeX
@article{Nuthall2026,
author = {Nuthall, Hugh N. and Kielbasa, William and Woerly, Eric M. and Hendle, Jorg and Goldsmith, Paul and Dubois, Susan L. and Zhang, Feiyu Fred and Donnelly, Kevin B. and Fleisher, Adam S. and Lowe, Stephen L. and Shcherbinin, Sergey and Winneroski, Leonard L. and Lopez, Jose E. and Dreyfus, Nicolas J.-F. and Evans, David A. and Lindsay-Scott, Peter J. and Rathmell, Richard E. and Gilmore, Jeremy and Collins, Emily C. and Mancini, Michele and Hutton, Michael and Mergott, Dustin J.},
title = {Discovery and Clinical Development of Ceperognastat, a Low-Dose, CNS-Penetrant O -Linked N -Acetylglucosaminidase Inhibitor},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c02053}
}
EUVIMED